GI CANCERS

A new integrated treatment regimen significantly enhances PFS vs standard chemotherapy in metastatic pancreatic cancer.

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid limited options.

A groundbreaking blood test for colorectal cancer shows enhanced sensitivity, promising earlier detection and improved patient outcomes in upcoming studies.

Jason S. Starr, DO, discusses his approach to dose reduction of cabozantinib in patients with neuroendocrine tumors.

CPI-008 receives orphan drug designation, enhancing surgical imaging for pancreatic cancer and promising improved outcomes in challenging surgeries.

Breakthroughs in GI cancer treatment in 2025 showcase innovative therapies, including daraxonrasib for pancreatic cancer and aspirin's role in colorectal cancer recurrence.

A new study reveals FOLFIRINOX chemotherapy is feasible for select elderly patients with pancreatic cancer, highlighting safety and survival outcomes.

FDA approves CBI-1214 for colorectal cancer, enabling fast-tracked clinical trials and highlighting innovative T-cell engager technology.

The FDA fast-tracks BGB-B2033, a promising bispecific antibody, for advanced hepatocellular carcinoma, enhancing treatment options for patients.

Maen Abdelrahim, MD, PhD, discusses how to manage the dose of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma.

Pelareorep shows promising results in treating KRAS-mutant metastatic colorectal cancer, achieving a 33% response rate and improved survival outcomes.

FDA fast-tracks muzastotug and pembrolizumab for metastatic colorectal cancer, showcasing promising efficacy and safety in early studies.

Givastomig shows promising antitumor activity and a manageable safety profile in patients with CLDN18.2-positive gastroesophageal carcinoma.

FDA approves durvalumab with FLOT chemotherapy for early-stage gastric cancer, showing promising survival rates in recent clinical trials.

Recent research reveals that GLP-1 receptor agonists significantly lower 5-year mortality rates in colon cancer patients, highlighting their potential in cancer treatment.

A novel combination therapy shows promising results in extending progression-free survival for patients with advanced pancreatic cancer, highlighting potential biomarkers for immunotherapy.

OBI-902 receives FDA orphan drug designation for cholangiocarcinoma, promising new hope in treating this rare and aggressive cancer.

DPTX3186 gains FDA fast track status, promising a novel treatment for gastric cancer with potential for significant patient impact.

Zanidatamab plus chemotherapy shows significant survival benefits for HER2-positive gastroesophageal adenocarcinoma, potentially transforming first-line treatment options.

The FDA accepts 177Lu-edotreotide for GEP-NETs, showcasing significant survival benefits over everolimus in recent trials.

FDA fast-tracks alnodesertib and irinotecan for ATM-negative metastatic colorectal cancer, showing promising efficacy and safety in early trials.

A new treatment combination shows significant promise for patients with resistant gastrointestinal stromal tumors, improving survival rates and tolerability.

New findings reveal promising antitumor responses in HER2-positive esophagogastric adenocarcinoma with a novel chemoimmunotherapy approach.

A phase 1b trial reveals the safety and potential efficacy of combining PolyPEPI1018 vaccine with TAS-102 in treating advanced colorectal cancer.

The EDGE-Gastric trial reveals promising results for domvanalimab and zimberelimab in treating advanced gastric cancer, showcasing durable efficacy and manageable safety.